Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$0.13 - $0.38 $26,889 - $78,599
206,842 New
206,842 $27,000
Q1 2022

May 16, 2022

SELL
$1.61 - $5.2 $127,561 - $412,001
-79,231 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.87 - $6.29 $129,692 - $284,238
45,189 Added 132.74%
79,231 $240,000
Q3 2021

Nov 15, 2021

SELL
$4.91 - $9.07 $344,696 - $636,741
-70,203 Reduced 67.34%
34,042 $212,000
Q2 2021

Aug 16, 2021

BUY
$7.82 - $13.8 $707,686 - $1.25 Million
90,497 Added 658.26%
104,245 $888,000
Q1 2021

May 17, 2021

BUY
$13.0 - $19.34 $178,724 - $265,886
13,748 New
13,748 $210,000

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Market Cap $2.87M
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.